8
MOH KS management guidelines Jane Bates Tiyanjane Clinic, QECH October 2009

MOH KS management guidelines

Embed Size (px)

DESCRIPTION

MOH KS management guidelines. Jane Bates Tiyanjane Clinic, QECH October 2009. Criteria for vincristine. Clinical diagnosis of KS. Tested for HIV. On ARVs for at least 3 months. advanced and / or progressive disease (check FBC) - consider vincristine. improving and / or stable disease - PowerPoint PPT Presentation

Citation preview

Page 1: MOH KS management guidelines

MOH KS management guidelines

Jane BatesTiyanjane Clinic, QECH

October 2009

Page 2: MOH KS management guidelines

Criteria for vincristine

Tested for HIV

advanced and / or progressive disease (check FBC)- consider vincristine

Clinical diagnosis of KS

On ARVs for at least 3 months

improving and / or stable disease - hold vincristine

High priority Medium Priority consider continue ARVSmay start before unilat or biilat. leg if exclusions 3 months ARVs completed KS limiting function apply confirmed or suspected oral lesions Pulmonary KS rapidly progressive maintain pain anddisease Involving face symptom control

Page 3: MOH KS management guidelines

ExclusionsAbsolute • severe peripheral neuropathy • unable to travel – financial or physical constraints• Hb < 8, platelet < 150• severe liver disturbance/diseaseRelative • near to another hospital site delivering

chemotherapy• minimal disease

Page 4: MOH KS management guidelines

2mg × six doses weeklySix week review If ‘no effect’, side effects and /or

limited stable disease - discontinueIf ‘good effect’, minimal side

effects and residual disease – continue

2mg × six doses fortnightly Review (as for six week review)2mg × six doses monthlyReview at end of schedule+ Review 3 months post treatment

Initial assessment visit

Page 5: MOH KS management guidelines

Pain and symptom control

• Assess and treat pain according to WHO analgesic ladder

• Salicylic acid cream/antihistamines for itching• Crushed metronidazole to reduce smell• potassium permanganate soaks to dry excess

oozing• Wound care, nutrition assessment and advice

Page 6: MOH KS management guidelines

WHO 3-stepLadder

1 mild1 mild

2 moderate2 moderate

3 severe3 severe

Morphine

± step 1 and/or Adjuvants

Morphine

± step 1 and/or Adjuvants

A/Codeine

A/Dihydrocodeine

Tramadol

± step 1 and/or Adjuvants

A/Codeine

A/Dihydrocodeine

Tramadol

± step 1 and/or Adjuvants

Aspirin

Paracetemol

NSAIDs

± Adjuvants

Aspirin

Paracetemol

NSAIDs

± Adjuvants

Page 7: MOH KS management guidelines

Drug type Drug name Dosage

(max daily dose)

Non opioids Paracetamol

Indomethacin

Aspirin

Brufen

1g qds (4g)

50mg tds (200mg)

300-900mg qds (4g)

400mg tds (2.4g)

Weak opioids Codeine

Dihydrocodeine

Compound preps

tramadol

30-60mg 4 hrly (240mg)

30mg 4-6 hrly (360mg)

2 tablets qds

50mg tds (400mg)

Strong opioids

Note : Pethidine is no longer recommended for treatment of chronic pain

Morphine Oral morphine solution, start at 2.5-5mg 4 hrly

MST, calculate according to need of oral solution (or start 10mg bd)

Page 8: MOH KS management guidelines

Other issues to consider

• This treatment regime is not curative• Patients/guardians need counselling about nature of

disease to assist with having realistic expectations• A major part of management is managing expectations

of patients, so information needs to be clear, consistent and honest

• At Tiyanjane we use a Chichewa information sheet for literate patients (double side A4) which you can have a copy of. If its of use photocopy and give out.

• If vincristine is not helping don’t continue it, aim for patient comfort and quality of life